Year: 2020

SOUTH ORANGE, NJ, Nov. 09, 2020 (GLOBE NEWSWIRE) — via NewMediaWire –Nephros, Inc. (Nasdaq: NEPH), a commercial-stage company that develops and sells high performance water purification products and pathogen detection systems to the medical and commercial markets, today announced that it will participate at the following investor conferences in November.Virtual Fall Investor SummitNovember 16, 20209:30 AM ETWebcast link: https://www.webcaster4.com/Webcast/Page/2038/38365https://investorsummitgroup.comCraig-Hallum Capital Group11th Annual Alpha Select ConferenceNovember 17, 2020Conference attendance is by invitation only: One-on-one and small group meetingshttps://www.craig-hallum.com/alpha-select/are-you-an-alpha-select-company/Sidoti Virtual Microcap ConferenceNovember 19, 202011:30 AM ETWebcast link: https://sidoti.zoom.us/webinar/register/WN_zzc86blrTGe68lysJNbIfAhttps://sidoticonference.comAbout...

LONDON and CARLSBAD, Calif., Nov. 09, 2020 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (NASDAQ: GWPH, GW, the Company or the Group), a world leader in the science, development, and commercialization of cannabinoid prescription medicines, today announced that the Company will present at the Stifel Virtual Healthcare Conference on Wednesday, November 18, 2020 at 1:20 pm EST.A live audio webcast of the presentation will be available through GW’s corporate website at www.gwpharm.com in the Investors section under Events & Presentations. A replay will be available soon after the live presentation.About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in...

VANCOUVER, British Columbia, Nov. 09, 2020 (GLOBE NEWSWIRE) — FPX Nickel Corp. (FPX-TSX.V) (“FPX Nickel” or the “Company”) is pleased to note the publication of new research estimating the carbon capture capacity of ultramafic rocks in British Columbia which highlights the potential for the development of a low- or zero-carbon mining operation at FPX Nickel’s Baptiste Project in the Decar Nickel District. The research is summarized in “The Carbon Mineralization Potential of Ultramafic Rocks in British Columbia: A Preliminary Assessment” (the “Report”), prepared by scientists from the University of British Columbia (“UBC”) with the support of Geoscience BC, the British Columbia Geological Survey, the Geological Survey of Canada, and FPX Nickel.HighlightsThe Report determines the “Carbon Mineralization Potential Index” for numerous...

Kalamazoo, Michigan, Nov. 09, 2020 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) announced today that Giovanni Caforio, M.D., Chairman and Chief Executive Officer of Bristol Myers Squibb, has been elected to its Board of Directors, effective December 1, 2020. “Giovanni adds extensive experience to our board as both a physician and business leader,” said Kevin Lobo, Chairman and Chief Executive Officer, Stryker. “As CEO of a leading global biopharmaceutical company, he has advanced scientific innovation that has helped improve the lives of patients. We look forward to welcoming Giovanni to our board.”Dr. Caforio has been CEO of Bristol Myers Squibb since May 2015 and assumed the role of Chairman of the Board in May 2017. As CEO, Dr. Caforio has led the company’s focus on researching and developing transformational medicines, which includes...

BRIDGEWATER, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) — Synchronoss Technologies Inc. (NASDAQ: SNCR), a global leader and innovator in cloud, messaging, digital and IoT platforms and products, today announced that it has been invited to participate in the ROTH Capital Technology Virtual Conference on November 11-12, 2020.Jeff Miller, Chief Executive Officer, and David Clark, Chief Financial Officer, will be available for 1×1 and small group virtual meetings with investors during the two days of the event. For those interested in registering for the event please email registration@roth.com or contact your ROTH representative.About ROTH Capital PartnersROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH...

Rekor’s AI-based platform will be integrated across the state to identify non-compliant vehiclesMany states face growing problem of uninsured vehicles on the roadCOLUMBIA, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) — Rekor Systems, Inc., (REKR) (“Rekor”) (the “Company”) a Maryland-based company providing real-time roadway intelligence through AI-driven decisions, today announced that the State of Oklahoma will integrate the Company’s Rekor One™ platform across the state to provide vehicle information associated with uninsured motorists as part of the state’s Uninsured Vehicle Enforcement Diversion Program (“UVED Program”), which is operated by the Oklahoma District Attorneys Council.Use of the Rekor One platform by Oklahoma’s UVED Program furthers the state’s mission to decrease the number of uninsured motorists on the road and keep matters...

NTLA-2001: First single-course therapy that potentially halts and reverses ATTR progressionFirst-ever in vivo CRISPR treatment delivered intravenously to a patientCAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), announced that the first patient has been treated with NTLA-2001, which the company is developing as a single-course, potentially curative therapy for transthyretin amyloidosis (ATTR). Intellia’s global Phase 1 study is to evaluate NTLA-2001 for hereditary ATTR with polyneuropathy (hATTR-PN). Following safety assessment and dose optimization, Intellia intends to further evaluate NTLA-2001 in a broader ATTR patient population of both polyneuropathy and cardiomyopathy patients.“With today’s news, we’re entering a new era of potential genome editing cures for patients,” said Intellia’s...

WALTHAM, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management will present at upcoming virtual investor conferences.Joshua Brumm, president and chief executive officer, and Romesh Subramanian, Ph.D., chief scientific officer, will participate in fireside chats at the following:Stifel 2020 Virtual Healthcare Conference; Monday, November 16, 2020 at 10:00 a.m. ETJefferies Virtual London Healthcare Conference; Thursday, November 19, 2020 at 7:55 a.m. ETPiper Sandler 32nd Annual Virtual Healthcare Conference; pre-recorded and expected to be available Monday, November 23, 2020Webcasts and recordings will be available in the Investors &...

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) — Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced plans to host a live webinar on Monday, November 16, 2020 at 8:00 a.m. ET highlighting its novel Immunosynthen STING-agonist ADC platform.The presentation will review the therapeutic rationale for the development of STING-agonist ADCs including preclinical mechanistic data showing STING activation in both tumor cells and tumor-resident immune cells, the development and optimization of the Immunosynthen platform, and preclinical data supporting the Company’s Immunosynthen ADC pipeline as well as the Investigational New Drug timeline for the Company’s...